July 18, 2018

Startup Neuraly raises $36M to bring potential disease-modifying treatments to patients with Parkinson’s disease. Research published in Nature Medicine demonstrates protection against dopamine loss and behavioral deficits associated with Parkinson’s disease

https://www.businesswire.com/news/home/20180718005208/en

June 28, 2018

Scientists at the Johns Hopkins Medical School have demonstrated that the experimental glucagon-like peptide 1 (GLP-1) receptor agonist NLY01 (Neuraly Inc.) was protective against Parkinson’s disease (PD) in two separate mouse models.

http://www.bioworld.com/content/diabetes-drug-affects-neurodegeneration-pd-immunity

June 13 2018

Activated microglia contribute to neurodegenerative diseases, and recent work suggests they do that, at least in part, by riling up normally protective astrocytes to attack and kill neurons. Can preventing astrocytes from going bad block the disease? Possibly, says a study in the June 12 Nature Medicine.

https://www.alzforum.org/news/research-news/does-taming-killer-astrocytes-spare-neurons-parkinsons-disease

October 30, 2017

Neuraly Inc., a startup from Johns Hopkins School of Medicine and South Korea-based 1st Biotherapeutics Inc. agreed to co-develop brain penetrant c-Abl inhibitors for Parkinson’s disease

http://www.bioworld.com/content/neuraly-1st-biotherapeutics-take-aim-parkinsons-brain-penetrant-c-abl-inhibitors